Quality of Life of Patients with Neurofibromatosis 1-Physical Disability Does Not Necessarily Result in Poor Mental Health

Overview

Journal Front Neurol

Specialty Neurology

Date 2024 Nov 14

PMID 39539654

Authors

Ute Bazner

Leonie Stauss

Thomas Kapapa

Christian Rainer Wirtz

Andrej Pala

Affiliations

Soon will be listed here.

Abstract

Introduction: Neurofibromatosis 1 (NF1) is a chronic neurocutaneous disease known to profoundly affect quality of life (QoL). We have performed an analysis of disease severity, mental and physical QoL and compare the different subclasses among patients with neurofibromatosis 1 (NF1).

Patients And Methods: We conducted a prospective analysis of 89 NF1 patients between January 2016 and March 2018. Data sourced from local records including demographic information, employment status, education level, and marital status. All patients completed 36-Item Short Form Health Survey (SF-36) and additionally the numerical pain rating scale (NPS). Patients were stratified based on severity of NF1, visibility and disease severity.

Results: Among 89 patients, severity was classified as grade 4 was identified in 42 (47.2%), moderate in 17 (19.1%), mild in 23 (25.8%) and minimal in 7 (7.9%) cases. According to visibility scale, severe grade 3 was found in 28 (31.5%), moderate grade 2 in 26 (29.2%) and mild grade in 35 (39.3%) cases. SF-36 data, except for pain, showed significantly lower values, if compared to the standard German population ( < 0.001, physical component summary = 0.045). Sex, marital status and education level did not significantly influence results. Employment was significantly associated with better mental and physical status ( = 0.028 and = 0.01 respectively) and age >40 was linked to lower physical ( = 0.027) but not mental component scores ( = 0.362). The numerical pain rating scale indicated pain levels of 7-10 in 9 cases (10,1%), 5-6 in 10 patients (11.2%), 1-4 in 26 patients (29.2%) and no pain in 44 cases (49.4%). Physical component scores significantly differed across different NPS grades ( < 0.001) but not in mental component scores (P = 0.06). Finally, no significant differences were found in mental component scores across severity or visibility grades.

Conclusion: Severity and visibility grades of patients with NF1 may not necessarily result in poor mental health. Symptomatic treatment should be considered even for severely disabled patients as they may have comparable QoL to less severely affected patients with NF1. Employment was linked to better quality of life outcomes in our findings.

References

Crow A, Janssen J, Marshall C, Moffit A, Brennan L, Kohler C . A systematic review and meta-analysis of intellectual, neuropsychological, and psychoeducational functioning in neurofibromatosis type 1. Am J Med Genet A. 2022; 188(8):2277-2292. PMC: 9302478. DOI: 10.1002/ajmg.a.62773. View

Brar K, Trivedi C, Kaur N, Adnan M, Patel H, Beg U . Prevalence of Psychiatric Comorbidities in Patients With Neurofibromatosis. Prim Care Companion CNS Disord. 2023; 25(5). DOI: 10.4088/PCC.23m03514. View

Cavallo N, Maietta P, Perrotta S, Moretta P, Carotenuto M, Esposito M . Quality of Life in Children with Neurofibromatosis Type 1: Agreement between Parents and Patients, and the Role of Disease Severity and Visibility. Children (Basel). 2024; 11(8). PMC: 11352328. DOI: 10.3390/children11081033. View

Hofmann S, Winkler S, Baumann M, Zellner H . Quality of Life in Children and Adolescents with Neurofibromatosis Type 1: A Single-Center Observational Study. Neuropediatrics. 2023; 54(6):430-432. DOI: 10.1055/s-0043-1768988. View

Benjamin C, Colley A, Donnai D, Kingston H, Harris R, Kerzin-Storrar L . Neurofibromatosis type 1 (NF1): knowledge, experience, and reproductive decisions of affected patients and families. J Med Genet. 1993; 30(7):567-74. PMC: 1016456. DOI: 10.1136/jmg.30.7.567. View

Garwood M, Bernacki J, Fine K, Hainsworth K, Davies W, Klein-Tasman B . Physical, cognitive, and psychosocial predictors of functional disability and health-related quality of life in adolescents with neurofibromatosis-1. Pain Res Treat. 2012; 2012:975364. PMC: 3463937. DOI: 10.1155/2012/975364. View

Sarwer D, Bartlett S, Whitaker L, Paige K, Pertschuk M, Wadden T . Adult psychological functioning of individuals born with craniofacial anomalies. Plast Reconstr Surg. 1999; 103(2):412-8. DOI: 10.1097/00006534-199902000-00008. View

Page P, Page G, Ecosse E, Korf B, Leplege A, Wolkenstein P . Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases. Am J Med Genet A. 2006; 140(18):1893-8. DOI: 10.1002/ajmg.a.31422. View

Andersson J, Sihto H, Meis-Kindblom J, Joensuu H, Nupponen N, Kindblom L . NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol. 2005; 29(9):1170-6. DOI: 10.1097/01.pas.0000159775.77912.15. View

10.

Bair M, Robinson R, Katon W, Kroenke K . Depression and pain comorbidity: a literature review. Arch Intern Med. 2003; 163(20):2433-45. DOI: 10.1001/archinte.163.20.2433. View

11.

Huson S, Compston D, Clark P, Harper P . A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet. 1989; 26(11):704-11. PMC: 1015740. DOI: 10.1136/jmg.26.11.704. View

12.

Hummelvoll G, Antonsen K . Young adults' experience of living with neurofibromatosis type 1. J Genet Couns. 2012; 22(2):188-99. DOI: 10.1007/s10897-012-9527-5. View

13.

Varni J, Seid M, Kurtin P . PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001; 39(8):800-12. DOI: 10.1097/00005650-200108000-00006. View

14.

Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C . Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006; 107(5):1065-74. DOI: 10.1002/cncr.22098. View

15.

Krueger G, Koo J, Lebwohl M, Menter A, Stern R, Rolstad T . The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001; 137(3):280-4. View

16.

Sanagoo A, Jouybari L, Koohi F, Sayehmiri F . Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study. BMC Neurol. 2019; 19(1):123. PMC: 6560778. DOI: 10.1186/s12883-019-1338-y. View

17.

Smith K, Wang D, Plotkin S, Park E . Appearance concerns among women with neurofibromatosis: examining sexual/bodily and social self-consciousness. Psychooncology. 2013; 22(12):2711-9. DOI: 10.1002/pon.3350. View

18.

Lehtonen A, Howie E, Trump D, Huson S . Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol. 2012; 55(2):111-125. DOI: 10.1111/j.1469-8749.2012.04399.x. View

19.

Kodra Y, Giustini S, Divona L, Porciello R, Calvieri S, Wolkenstein P . Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients. Dermatology. 2008; 218(3):215-20. DOI: 10.1159/000187594. View

20.

Ellert U, Kurth B . [Health related quality of life in adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013; 56(5-6):643-9. DOI: 10.1007/s00103-013-1700-y. View